Cytokinetics, Inc. to Present at May Healthcare Conferences

SOUTH SAN FRANCISCO, CA--(Marketwire - April 27, 2010) -

Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that members of its executive team are scheduled to present at the following three upcoming healthcare conferences throughout the month of May:

Deutsche Bank’s 35th Annual Health Care Conference
Date: Tuesday, May 4, 2010
Time: 10:00 a.m. Eastern Daylight Time
Location: InterContinental Hotel, Boston, Massachusetts
Presenter: Robert I. Blum, President and Chief Executive Officer

The Ninth Annual JMP Securities Research Conference
Date: Monday, May 10, 2010
Time: 3:00 p.m. Pacific Daylight Time
Location: The Ritz-Carlton Hotel, San Francisco, California
Presenter: Sharon A. Barbari, EVP Finance and Chief Financial Officer

Bank of America - Merrill Lynch 2010 Health Care Conference
Date: Tuesday, May 11, 2010
Time: 8:40 a.m. Eastern Daylight Time
Location: The Grand Hyatt Hotel, New York, New York
Presenter: Robert I. Blum, President and Chief Executive Officer

Interested parties may access the live audio webcast of these presentations and replays by visiting the Investor Relations section of the Cytokinetics website at www.cytokinetics.com. The webcast replay of these presentations will be archived on the Presentations page within the Investor Relations section of Cytokinetics’ website for two weeks following the completion of the event.

About Cytokinetics

Cytokinetics is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics that modulate muscle function for the potential treatment of serious diseases and medical conditions. Cytokinetics’ lead drug candidate from its cardiac muscle contractility program, omecamtiv mecarbil (formerly CK-1827452), is in clinical development for the potential treatment of heart failure. Amgen Inc. holds an exclusive license worldwide (excluding Japan) to develop and commercialize omecamtiv mecarbil and related compounds, subject to Cytokinetics’ specified development and commercialization participation rights. Cytokinetics is independently developing CK-2017357, a skeletal muscle activator, as a potential treatment for diseases and conditions associated with aging, muscle wasting or neuromuscular dysfunction. CK-2017357 is currently the subject of a Phase IIa clinical trials program and has been granted orphan-drug designation by the United States Food and Drug Administration (FDA) for the potential treatment of amyotrophic lateral sclerosis. Cytokinetics is also conducting non-clinical development of compounds that inhibit smooth muscle contractility and which may be useful as potential treatments for diseases and conditions such as systemic hypertension or bronchoconstriction. In addition, prior Cytokinetics’ research generated three anti-cancer drug candidates that have progressed into clinical development: ispinesib, SB-743921 and GSK-923295. All of these drug candidates and potential drug candidates have arisen from Cytokinetics’ research activities and are directed towards the cytoskeleton. The cytoskeleton is a complex biological infrastructure that plays a fundamental role within every human cell. Additional information about Cytokinetics can be obtained at www.cytokinetics.com.

This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the “Act”). Cytokinetics disclaims any intent or obligation to update these forward-looking statements, and claims the protection of the Act’s safe harbor for forward-looking statements. Examples of such statements include, but are not limited to, statements relating to planned presentations, and the properties and potential benefits of Cytokinetics’ drug candidates and potential drug candidates. Such statements are based on management’s current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to, potential difficulties or delays in the development, testing, regulatory approval and production of Cytokinetics’ drug candidates and potential drug candidates that could slow or prevent clinical development or product approval, including risks that current and past results of clinical trials or preclinical studies may not be indicative of future clinical trials results and that Cytokinetics’ drug candidates and potential drug candidates may have unexpected adverse side effects or inadequate therapeutic efficacy. For further information regarding these and other risks related to Cytokinetics’ business, investors should consult Cytokinetics’ filings with the Securities and Exchange Commission.